# DESCRIPTION

## BACKGROUND OF THE INVENTION

## SUMMARY OF THE INVENTION

## DETAILED DESCRIPTION OF THE INVENTION

### Targeting Ligands

### Linkers

### Degrons

### Methods of Synthesis

### Proteins of Interest

### Methods of Use

### Chimeric Antigen Receptor Protein (CAR)-dTAG Fusion Proteins

### Dosage Amounts

### Pharmaceutical Kits

## EXAMPLES

### Example 1: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (1)

### Example 2: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2R,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (2)

### Example 3: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(((S)-16-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (3)

### Example 4: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(O)-16-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (9-14(9-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (4)

### Example 5: Anti-Proliferation in NIH/3T3 Cells Expressing FKBP12F36V-KRASG12V by ATPlite™ Assay

### Example 6: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

### Example 7: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

### Example 8: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V; KRAS−/− Clone

### Example 9: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V KRAS−/− Clone

